首页> 外文期刊>Journal of endourology >MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men
【24h】

MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men

机译:MRI融合靶向癌症前列腺活检和前列腺特异性抗原密度和前列腺健康指数检测东南亚男性临床显着的前列腺癌的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To test the hypothesis that targeted biopsy has a higher detection rate for clinically significant prostate cancer (csPCa) than systematic biopsy. We defined csPCa as any Gleason sum 7 cancer. In patients with Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, to determine if factors, such as prostate-specific antigen density (PSAD) and prostate health index (PHI), can predict csPCa and help select patients for biopsy. Materials and Methods: We report the first series of targeted biopsies in Southeast Asian men, with comparison against systematic biopsy. Consecutive patients were registered into a prospective institutional review board-approved database in our institution. We reviewed patients who underwent biopsy from May 2016 to June 2017. Inclusion criteria for our study were patients with at least one PI-RADS 3, and who underwent both targeted and systematic biopsies in the same sitting. Results: There were 115 patients in the study, of whom 74 (64.3%) had a previous negative systematic biopsy. Targeted biopsies detected significantly less Gleason 6 cancers than systematic biopsies (p<0.01), and demonstrated significantly higher sensitivity, specificity, positive predictive value, and negative predictive value (NPV) for the detection of csPCa. For patients with PI-RADS 3 lesions, PHI and PSAD were found to be the best predictors for csPCa. PSAD <0.10ng/mL/mL had an NPV of 93% and sensitivity of 92%, while allowing 20% of patients to avoid biopsy. PHI cutoff of <27 would allow 34% of patients to avoid biopsy, with both sensitivity and NPV of 100%. Conclusions: Targeted prostate biopsies were found to be significantly superior to systematic biopsies for the detection of csPCa, while detecting less Gleason 6 cancer. Usage of PSAD and PHI cutoff levels in patients with PI-RADS 3 lesions may enable a number of patients to avoid unnecessary biopsy.
机译:目的:测试靶向活组织检查在临床上有明显的前列腺癌(CSPCA)的检测率较高的假设,而不是系统的活组织检查。我们将CSPCA定义为任何Gleason Sum 7癌症。在患有前列腺成像报告和数据系统(PI-rads)3病变的患者中,以确定因素,如前列腺特异性抗原密度(PSAD)和前列腺健康指数(PHI),可以预测CSPCA,并帮助选择患者的活组织检查。材料和方法:我们在东南亚男性中报告了第一个有针对性活组织检查,与系统活检相比。连续患者注册到我们机构核准的潜在机构审查委员会核查数据库中。我们审查了2016年5月至2017年6月接受活检的患者。纳入标准是我们的研究的患者,至少有一个PI-RAD 3,并且在同一坐骑中接受了靶向和系统的活组织检查。结果:研究中有115名患者,其中74名(64.3%)具有先前的负系统活检。靶向活组织检查显着较小的肠胃胺6癌症而不是系统活组织检查(P <0.01),并证明了用于检测CSPCA的敏感性,特异性,阳性预测值和阴性预测值(NPV)。对于PI-rads 3病变的患者,发现PHI和PSAD是CSPCA的最佳预测因子。 PSAD <0.10ng / ml / ml的NPV为93%,敏感性为92%,同时允许20%的患者避免活组织检查。 PHI截止<27的抑制将允许34%的患者避免活组织检查,敏感性和NPV为100%。结论:靶向前列腺活组织检查被发现显着优于检测CSPCA的系统活组织检查,同时检测较少的GLEASON 6癌症。 PI-rads 3病变患者的PSAD和PHI截止水平的用途可以使许多患者能够避免不必要的活组织检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号